TMO trades against a final fair-value range of $384.14-$618.78, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $384, high $619, with mid-point at $501.
Stock analysis
Thermo Fisher Scientific Inc.TMO Thermo Fisher Scientific Inc. fair value $501–$619
Trades at a measured discount to fair value with adequate margin of safety.
Fair value
$501
Margin of safety
+5.3%
Confidence
88/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$474.46Price
FV $500.89
High $618.78
TMO trades against a final fair-value range of $384.14-$618.78, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
High Switching Costs
High Switching Costs
Unmatched Scale
Unmatched Scale
Cycle upside
Accelerating biopharma R&D spend, robust FDA approvals, and strong academic funding drive demand for tools and bioproduction.
Based on our latest independent analysis, TMO looks modestly undervalued. The current price is $474 versus a composite fair-value midpoint of $501 (range $384–$619), which implies roughly 5.6% upside to the midpoint.
Our composite fair-value range for TMO is $384–$619, with a midpoint of $501. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for Thermo Fisher Scientific Inc.'s archetype.
Our current rating for TMO is Hold with a confidence score of 88/100. TMO is rated Hold at $474.46 versus the reconciled fair value midpoint of $500.89, implying +5.57% upside/downside. Confidence is separately disclosed at 88/100. This is independent research for educational purposes, not personalized investment advice.
The top risks our latest report flags for Thermo Fisher Scientific Inc. are: Prolonged Biopharma Funding Winter; M&A Engine Stalls Under Debt Load; Severe Integration Failure. The single biggest risk is Prolonged Biopharma Funding Winter: Extended depression in early-stage biotech funding permanently impairs the growth trajectory of the life sciences solutions segment.
Our current rating for TMO is Hold, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($384–$619) versus the current price of $474.
Thermo Fisher Scientific Inc. is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for TMO.
